Citi Sticks to Its Hold Rating for Astellas Pharma (ALPMF)
Citi analyst maintained a Hold rating on Astellas Pharma on January 16 and set a price target of Yen2,500.00. The company’s shares closed last Monday at Yen2,244.00.
Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
In addition to Citi, Astellas Pharma also received a Hold from Bernstein’s Miki Sogi in a report issued on January 16. However, on the same day, TipRanks – xAI reiterated a Buy rating on Astellas Pharma (Other OTC: ALPMF).
ALPMF market cap is currently Yen4040.9B and has a P/E ratio of 32.19.
This article contains syndicated content. We have not reviewed, approved, or endorsed the content, and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here.
This section contains press releases and other materials from third parties (including paid content). The Globe and Mail has not reviewed this content. Please see disclaimer.